Loading
A company that makes drugs for other companies. Most ADCs, biologics, and cell therapies are made by a handful of them.
A CDMO, or contract development and manufacturing organisation, is a company that makes drugs for other companies, and most ADCs, biologics and cell therapies are made by a handful of them. Capacity, containment for highly potent ADC payloads and regulatory track record at CDMOs such as Lonza, WuXi, Samsung Biologics and Catalent set the timelines for the whole field. Geopolitical measures, notably the US BIOSECURE Act of 2024 to 2025, are reshaping sourcing away from China-based sites. The term is linked to the technologies ADC bioconjugation manufacturing (CDMOs), Viral vector manufacturing (lentiviral, retroviral, AAV) and Sterile fill-finish and lyophilisation, and to the related term BIOSECURE Act. It is referenced by the company records for Lonza and OXB (Oxford Biomedica).
Showing the technology this term belongs to: ADC bioconjugation manufacturing (CDMOs).
Shares BIOSECURE Act, ADC bioconjugation manufacturing (CDMOs).
Shares Sterile fill-finish and lyophilisation, Viral vector manufacturing (lentiviral, retroviral, AAV).
Shares ADC bioconjugation manufacturing (CDMOs), Sterile fill-finish and lyophilisation.
Shares Lonza, ADC bioconjugation manufacturing (CDMOs), Sterile fill-finish and lyophilisation.
Shares Lonza, ADC bioconjugation manufacturing (CDMOs), Sterile fill-finish and lyophilisation.
Shares Lonza, ADC bioconjugation manufacturing (CDMOs), Sterile fill-finish and lyophilisation.